Highly commended
The Takeda Transplant Exchange: Connecting Transplant Care Specialists Across Channels
Summary of work
Cytomegalovirus (CMV) poses a serious threat to transplant patients due to immunosuppression used to avoid rejection. Transplant practitioners work across disparate organ specialisms and opportunities to connect are rare, so there was a real need to bring this clinical community together. With a recently launched treatment for refractory CMV (LIVTENCITY [maribavir]) and experience in medical education, Takeda was well placed to foster shared learning with meaningful, peer-led education via the Transplant Exchange Meeting II (TEM II). Combining digital, print, congress, and F2F formats, TEM II delivered a personalised engagement journey. TEM I insights shaped every stage from co-created content to a dynamic two-day event featuring 22 speakers and 16 patient cases. A highlights reel was shared with 780 customers post event, and further assets will be hosted on Takeda’s Rare Disease Hub later this year. TEM II achieved exceptional results: 70/81 registrants attended, with strong engagement metrics and survey scores showing significant shifts in understanding and confidence, and intent to change clinical practice. Familiarity with LIVTENCITY’s data rose from 30% to 93%, and 90% of attendees reported high confidence to switch early when first-line therapy fails. TEM II set new benchmarks in transplant education, empowering clinicians through shared experience.
Judges’ comments
“The Takeda Transplant Exchange” was a well-planned, very focused small event with a clear submission. It showed results in clinician knowledge, confidence, and even treatment guidelines. It was a strong submission, demonstrating an integrated approach, with clarity in the strategic priorities to deliver on and highly effective in its execution. The approach clearly provided value add to the clinicians and thus achieved a significantly higher level of engagement than had been previously possible.
